Immunicon: Advanced Anticancer Technology
By Kathryn Ward
Byron Hewett

Fighting cancer is a mission at Immunicon. Founded in 1983 by a professor at Thomas Jefferson University, a leading Philadelphia medical and health sciences university, Immunicon provides researchers and diagnosticians with cell-analysis systems enabling them to capture, count, and characterize rare cells such as circulating tumor cells in cancer patients. The company received FDA approval in December 2006 for the use of its CellSearch Circulating Tumor Cell Kit for breast cancer detection, and it's seeking FDA approval for the product to be used for detecting prostate and colorectal cancer.

The publicly held NASDAQ company is based in Huntingdon Valley, Pa., and for 2006, the firm reported $8 million in revenue, a one-year...

Interested in reading more?

Magaizne Cover

Become a Member of

Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member?